Neos Therapeutics Inc (NASDAQ:NEOS) has earned a consensus rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $15.33.
Several equities analysts recently issued reports on NEOS shares. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 1st. BidaskClub upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. BMO Capital Markets cut Neos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Zacks Investment Research cut Neos Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. Finally, Cowen reiterated a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th.
A number of institutional investors and hedge funds have recently modified their holdings of the business. TIAA CREF Investment Management LLC boosted its holdings in Neos Therapeutics by 4.9% during the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock worth $342,000 after buying an additional 2,168 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Neos Therapeutics by 14.1% during the third quarter. California State Teachers Retirement System now owns 38,915 shares of the company’s stock worth $356,000 after buying an additional 4,800 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Neos Therapeutics by 13.0% during the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock worth $396,000 after buying an additional 6,223 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in Neos Therapeutics by 67.3% during the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock worth $159,000 after buying an additional 7,000 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Neos Therapeutics by 34.5% during the fourth quarter. Alliancebernstein L.P. now owns 29,600 shares of the company’s stock worth $302,000 after buying an additional 7,600 shares during the last quarter. Hedge funds and other institutional investors own 51.55% of the company’s stock.
Neos Therapeutics (NEOS) opened at $9.25 on Friday. The stock has a market capitalization of $268.22 and a PE ratio of -2.70. Neos Therapeutics has a 1-year low of $5.20 and a 1-year high of $13.15. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 4.01.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/19/brokerages-set-neos-therapeutics-inc-neos-price-target-at-15-33.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.